de la Torre-Anderson J, de la Torre-Buendía J, Zamora-García V

Language: Spanish
References: 20
Page: 77-82
PDF size: 235.37 Kb.

ABSTRACT

Background: Sugammadex is a gamma-cyclodextrin used to reverse the neuromuscular blockade induced by aminosteroid blockers of rocuronium or vecuronium. The objective of this study was to show the experience with sugammadex in open population. Methods: Design: Retrospective, longitudinal and observational study. Setting: Beneficencia Española de la Laguna (Sanatorio Español) and Unidad Médica de Alta Especialidad No. 71, IMSS. Period: Eight months. Patients: Surgical subjects who received rocuronium. Maneuver: Administration of sugammadex. Depth of the block was classified according to the observed response in the neuromuscular monitoring (TOF Watch^® SX, Organon), using two patterns of stimulation, post-tetanic count and train-of-four. Doses of 2, 4 and 16 mg/kg of sugammadex were used for reversion of the effects of rocuronium. Variables: Demographics, clinical, surgical, anesthetic and adverse events. Statistical analysis: Descriptive and inferential statistics. Results: There were 233 patients, 126 women (54.1%) and 17 men (45.9%). Mean age was 39.0 ± 16.6 years. There were 158 elective surgeries and 75 urgent surgeries (32.2%). General anesthesia was used in all patients. Depth of block was moderate in 158 cases (67.8%), intense in 16 (6.9%) and deep in 59 (25.3%), respectively. Conclusions: Sugammadex showed efficacy and safety in Mexican population with high diversity of surgeries both on the government context and on the private context. Then, results of this study are generalizable to all population.

REFERENCES

1. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042–1048.

2. van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg. 1997;84:148–154.

3. Eikermann M, Fassbender P, Malhotra A, Takahashi M, Kubo S, Jordan AS, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology. 2007;107:621-629.

4. Gómez HA, Bello FR, Lister PA. Sugammadex: presente y futuro. Rev Cub Anest Reanim. 2010;9:3-11.

5. Karalapillai D, Kaufman M, Weinberg L. Sugammadex. Crit Care Resusc. 2013;15:57-62.

6. Caldwell JE, Miller RD. Clinical implications of sugammadex. Anaesthesia. 2009;64:66-72.

7. Carrillo-Esper R, Sánchez-García R, Jiménez-Morales EE. Sugammadex. Nueva alternativa para la reversión de la relajación neuromuscular. Rev Mex Anestesiol. 2008;31:139-145.

8. Abrishami A, Ho J, Wong J, Yin L, Chung F. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Anesth Analg. 2010; 110: 1239.

9. Mirakhur RK. Sugammadex in clinical practice. Anaesthesia. 2009;64:45-54.

10. De Boer HD. Neuromuscular transmission: new concepts and agents. J Crit Care. 2009;24:36-42.

11. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009;4:CD007362.

12. Bom A, Hope F, Rutherford S, Thompson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24:29-35.

13. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009;69:919-942.

14. Cammu GV, Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery. Anaesth Intensive Care. 2012;40:999-1006.

15. Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012;67:991-998.

16. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106:283-288.

17. Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Craig D, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010;14:1-211.

18. Barajas R, Camarena J, Castellanos A, Castilleros OA, Castorena G, De Anda D, et al. Determinación de la incidencia de la parálisis residual postanestésica con el uso de agentes bloqueadores neuromusculares en México. Rev Mex Anestesiol. 2011;34:181-188.

19. Pasic E, Castorena-Arellano G, Calderón-Vidal M. Incidence and risk factors for postoperative residual paralysis. Rev Mex Anestesiol. 2011;34:270-273.

20. Dubois PE, Mulier JP. A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium. Acta Anaesthesiol Belg. 2013;64:49-60.